Cistron Biotechnology(CIST)$.30 Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Raptech who wrote (2723)	9/5/2000 9:49:14 AM
From: Walter Morton	of 2742

Cistron also announced today that the merger agreement has been amended to eliminate the provision for payment of up to $3.5 million in cash and up to $3.5 million in Celltech stock to Cistron stockholders in the event that Aventis Pasteur, subsidiary of Aventis S.A. (NYSE: AVE - news), exercised the options previously granted by Cistron to acquire exclusive licenses to use the IL-1 beta technology in the fields of therapeutic and preventative vaccines. The merger agreement was amended following termination of a collaboration and option agreement on August 24 [what year?] between Cistron and Aventis Pasteur, including Aventis Pasteur's right to exercise options to acquire licenses to the IL-1 beta technology. So, why hasn't the offer been amended for the co-patent agreement between Duke University and Cistron? Message 13822280

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next